
Based on short reviews of zzso zzso zzso zzso breast and zzso cancer, there remain significant differences between Japan and the West in the therapeutic regimen for most zzso Some of the differences are due to differences in stage of disease at diagnosis or historical factors affecting availability of zzso In both Japan and the West, there are initiatives to prepare treatment guidelines based on published zzso For Japan this initiative is limited by the lack of Japanese clinical trial data or even safety zzso When guidelines are prepared from international data, many of the products have limited indications in Japan and therefore not zzso zzso of the most appropriate therapies to Japanese patients will depend on a zzso of clinical trials in both primary and additional zzso However, the experience in other countries is that, even where data and registration approval are available, guidelines are hard to agree and are not zzso accepted by zzso The zzso zzso zzso on the use of bridging studies to zzso Western data to Japanese regulatory dossiers provides an opportunity to accelerate availability of new medicines to Japanese zzso and zzso The use of bridging studies has so far been limited for zzso zzso Where relevant zzso zzso can be measured, zzso zzso zzso there can increase confidence in zzso The newer types of agent which act to zzso disease rather than zzso shrinkage present a special zzso In some cases surrogate markers can be valuable but in each case they need to be zzso As globalization continues, an alternative approach is to include a significant cohort of Japanese patients in Japanese patients but this depends on sufficient similarity in the patient population and background zzso The most significant limitation to either large outcome studies in Japan or for Japanese centers to join international trials has been the environment for conduct of clinical zzso There have been some recent improvements and further progress is expected so that Japanese doctors can play a full role in the evaluation of new zzso 

